Chief Legal Officer and Corporate Secretary · ENANTA PHARMACEUTICALS INC (ENTA)

Nathaniel Gardiner

A named executive officer of ENANTA PHARMACEUTICALS in every fiscal year CompBrief holds from FY2016 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,855,081

Salary $475,275Stock awards $1,146,600

FY2022: $2,382,727

2nd of 6 named executive officers at Enanta Pharmaceuticals by FY2023 total.

6 named officers on file for ENANTA PHARMACEUTICALS, FY2023

Nathaniel Gardiner’s pay file — $29

  • 8 fiscal years of pay, line by line
  • 12 equity grants, each cited to its filing
  • ENTA’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how ENANTA PHARMACEUTICALS’s whole pay program stands against its peers

  • ENANTA PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ENTA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed January 26, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Nathaniel Gardiner’s full pay file as a PDF — free

More than this page: up to 10 years of Nathaniel’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Nathaniel Gardiner compensation by year

ENANTA PHARMACEUTICALS Summary Compensation Table · all 8 fiscal years held
In US dollars, as ENANTA PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023
Salary$353,403$368,100$398,850$398,850$431,025$444,675$458,050$475,275
Bonus$0$0$0$0$0$0$0$0
Stock awards$94,175$545,550$232,925$232,925$187,821$582,640$739,664$1,146,600
Option awards$505,986$428,275$577,165$577,165$981,504$652,535$985,114$1,035,806
Non-equity incentive$116,764$151,200$148,320$142,396$169,470$198,702$180,475$176,802
Pension and deferred compensation$0$0$0$0$0$0$0$0
All other$15,857$18,551$18,851$18,851$19,171$19,211$19,424$20,598
Total$1,086,185$1,511,676$1,376,111$1,370,187$1,788,991$1,897,763$2,382,727$2,855,081

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ENANTA PHARMACEUTICALS INC DEF 14A filed January 26, 2024, accession 0000950170-24-007956, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ENANTA PHARMACEUTICALS INC filed document, accession 0000950170-24-007956. Every figure is read from that document and cited to the page and table it appears in. Filed January 26, 2024.

$1.1M
$1.5M
$1.4M
$1.4M
$1.8M
$1.9M
$2.4M
$2.9M
FY16
FY17
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
RSU5,100$56,967—
PSU5,000$55,850—
PSU5,000$55,850—
PSU4,150$46,356—
PSU4,150$46,356—
RSU3,800$42,446—
Option36,563—$45.00
Option9,625—$43.57
Option15,975—$75.33
Option1,875—$63.35

Per the Outstanding Equity Awards at Fiscal Year-End table in ENANTA PHARMACEUTICALS INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

4 Form 4 lines since the FY2023 proxy (filed January 26, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2024-02-26Exercise or conversion derivative—5,187$0.0077,813
2024-02-26Exercise or conversion—5,187$8.9975,688
2024-02-12Tax withholding—973$12.4170,501
2024-02-12Grant or award—3,320$0.0071,474

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

ENANTA PHARMACEUTICALS’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Jay LulyPresident and Chief Executive Officer$7,856,698
Nathaniel Gardiner · this pageChief Legal Officer and Corporate Secretary$2,855,081
Paul MellettChief Financial and Administrative Officer$2,849,250
Brendan LuuChief Business Officer$2,577,672
Yat Sun OrChief Scientific Officer$2,469,600
Scott RottinghausChief Medical Officer$1,654,724

The full ENANTA PHARMACEUTICALS compensation record

free company brief

This page is one person within ENANTA PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the ENANTA PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ENANTA PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Nathaniel Gardiner's compensation dossier · One-time report. No refunds.